Renal Cancer Detection With Liquid Biopsy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorZealand University Hospital
About this trial
Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer.
For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)
Sign up information consent
Can perform protocol procedure
Disqualifiers
Non-clear cell Renal cell carcinoma
RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.
Trial population
All patients referred to our department by family doctors or the primary sector with a suspicion of renal tumor by CT-scanning will be asked to participate in the study. Patients with suspected small renal tumor will be offered renal tumor biopsies as standard procedure.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
GaGnostic
Diagnostic testPlasma
GaGnostic
Diagnostic testSerum
GaGnostic
Diagnostic testUrine
Treatment groups
200 Participants
are divided into 3 treatment groupsGroup A: Renal Call Carcinoma1 intervention
Group B: Oncocytoma1 intervention
Group C: Healthy persons1 intervention
Trial outcomes
Primary outcomes
1
To identify the optimal GAG score
To identify the optimal GAG score in RCC patients
Time frame
2 years2
To identify the optimal GAG score
To identify the optimal GAG score in oncocytoma
Time frame
2 years3
To identify the optimal GAG score
To identify the optimal GAG score in healthy individuel
Time frame
2 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov